Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

Insulet will webcast its Bernstein healthcare forum presentation, offering investors online live and replay access.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3^rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).

The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260918467416/en/

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com

Media:
Joan Campion
Vice President, External Communications
pr@insulet.com

Source: Insulet Corporation

Key Terms

automated insulin delivery system medical

An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.

continuous glucose monitor medical

A continuous glucose monitor is a small device worn on the body that constantly tracks blood sugar levels throughout the day and night. It provides real-time data, helping individuals manage conditions like diabetes more effectively. For investors, advancements in this technology can signal growth opportunities in healthcare and medical device markets, reflecting broader trends in health technology innovation.

subcutaneous medical

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.